SCYNEXIS INC — Investor Relations & Filings
SCYNEXIS, Inc. is a biotechnology company focused on the discovery and development of novel anti-infectives to overcome difficult-to-treat and drug-resistant fungal infections. The company is pioneering a new class of broad-spectrum antifungal agents called 'fungerps,' which are triterpenoid-based compounds. These agents are being developed in both oral and intravenous formulations to treat a range of serious, invasive, and life-threatening fungal diseases, particularly those encountered in hospital environments. SCYNEXIS aims to address the significant global health threat of antifungal resistance by providing innovative therapeutic options where existing treatments are limited or ineffective. The company's development pipeline includes second-generation fungerp candidates.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-29 | English | |
| 8-K | 2026-05-22 | English | |
| 10-Q - SCYNEXIS INC (0001178253) (Filer) | 2026-05-11 | English | |
| 424B3 - SCYNEXIS INC (0001178253) (Filer) | 2026-05-08 | English | |
| S-3 - SCYNEXIS INC (0001178253) (Filer) | 2026-05-01 | English | |
| DEF 14A - SCYNEXIS INC (0001178253) (Filer) | 2026-04-27 | English |
Browse filings by year
19 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 47893649 | 8-K | 2026-05-29 | English | ||
| 46858968 | 8-K | 2026-05-22 | English | ||
| 44997838 | 10-Q - SCYNEXIS INC (0001178253) (Filer) | 2026-05-11 | English | ||
| 44431871 | 424B3 - SCYNEXIS INC (0001178253) (Filer) | 2026-05-08 | English | ||
| 39620669 | S-3 - SCYNEXIS INC (0001178253) (Filer) | 2026-05-01 | English | ||
| 37621661 | DEF 14A - SCYNEXIS INC (0001178253) (Filer) | 2026-04-27 | English | ||
| 34693711 | 8-K - SCYNEXIS INC (0001178253) (Filer) | 2026-04-20 | English | ||
| 33121988 | 8-K - SCYNEXIS INC (0001178253) (Filer) | 2026-03-31 | English | ||
| 33112954 | 8-K - SCYNEXIS INC (0001178253) (Filer) | 2026-03-31 | English | ||
| 33112623 | 8-K - SCYNEXIS INC (0001178253) (Filer) | 2026-03-31 | English | ||
| 28389174 | 4 Filing | 2026-02-02 | English | ||
| 28389138 | 4 Filing | 2026-02-02 | English | ||
| 28389127 | 4 Filing | 2026-02-02 | English | ||
|
2025
2 filings
| |||||
| 11544971 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 11544973 | Major Shareholding Notification 2025 | 2025-11-12 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
SCYNEXIS INC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34648/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34648 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34648 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34648 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34648}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for SCYNEXIS INC (id: 34648)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.